{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:26:26Z","timestamp":1791613586282,"version":"4.3.4"},"reference-count":12,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,11,3]],"date-time":"2014-11-03T00:00:00Z","timestamp":1414972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:p>\n                    We compared the efficacy of twice\u2010daily doses of remogliflozin etabonate (\n                    <jats:styled-content style=\"fixed-case\">RE<\/jats:styled-content>\n                    ) and once\u2010daily pioglitazone with placebo for reduction in glycated haemoglobin (\n                    <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                    ) concentration. In this 12\u2010week, double\u2010blind, randomized, active\u2010 and placebo\u2010controlled trial, 336 treatment\u2010na\u00efve subjects with type 2 diabetes and an\n                    <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                    of 7.0\u20139.5% (53\u201380\u2009mmol\/mol) were randomized to\n                    <jats:styled-content style=\"fixed-case\">RE<\/jats:styled-content>\n                    (50, 100, 250, 500 or 1000\u2009mg twice daily), matching placebo or 30\u2009mg pioglitazone once daily. The primary endpoint was change in\n                    <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                    from baseline. Other endpoints included changes in body weight, lipid levels, safety and tolerability.\n                    <jats:styled-content style=\"fixed-case\">RE<\/jats:styled-content>\n                    produced a decreasing dose response in\n                    <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                    at week 12 (p\u2009&lt;\u20090.001), with reductions in\n                    <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                    versus placebo ranging from 0.64 to 1.07% (p\u2009&lt;\u20090.001). Statistically significant reductions in body weight for\n                    <jats:styled-content style=\"fixed-case\">RE<\/jats:styled-content>\n                    compared with placebo were also observed. Twice\u2010daily\n                    <jats:styled-content style=\"fixed-case\">RE<\/jats:styled-content>\n                    resulted in a dose\u2010ordered improvement in glycaemic control and was generally well tolerated.\n                  <\/jats:p>","DOI":"10.1111\/dom.12391","type":"journal-article","created":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T08:21:14Z","timestamp":1410769274000},"page":"94-97","source":"Crossref","is-referenced-by-count":31,"title":["Randomized trial showing efficacy and safety of twice\u2010daily remogliflozin etabonate for the treatment of type 2 diabetes"],"prefix":"10.1111","volume":"17","author":[{"given":"A. P.","family":"Sykes","sequence":"first","affiliation":[{"name":"Metabolic Pathways and Cardiovascular GlaxoSmithKline  Uxbridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"O'Connor\u2010Semmes","sequence":"additional","affiliation":[{"name":"Center for Metabolic Disease GlaxoSmithKline  Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dobbins","sequence":"additional","affiliation":[{"name":"Center for Metabolic Disease GlaxoSmithKline  Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Dorey","sequence":"additional","affiliation":[{"name":"Clinical Statistics GlaxoSmithKline  Mississauga Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. D.","family":"Lorimer","sequence":"additional","affiliation":[{"name":"Metabolic Pathways and Cardiovascular GlaxoSmithKline  Uxbridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Walker","sequence":"additional","affiliation":[{"name":"Islet Sciences, Inc.  Raleigh NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. O.","family":"Wilkison","sequence":"additional","affiliation":[{"name":"Islet Sciences, Inc.  Raleigh NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kler","sequence":"additional","affiliation":[{"name":"Metabolic Pathways and Cardiovascular GlaxoSmithKline  Uxbridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,11,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00982.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.243"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-012-0275-6"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01462.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.4.838"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2307\/2530666"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39043.398738.DE"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jada.2007.10.003"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01659.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1926"},{"key":"e_1_2_7_12_1","article-title":"Randomized efficacy and safety trial of once daily remogliflozin etabonate for the treatment of type 2 diabetes mellitus","author":"Sykes AP","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-14-25"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12391","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:13:56Z","timestamp":1761862436000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,3]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/dom.12391"],"URL":"https:\/\/doi.org\/10.1111\/dom.12391","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,3]]}}}